An enhanced version of an immunotherapy drug has shown significant promise against aggressive cancers in phase-1 trials, according to researchers ...

This first approved medical therapy for RRP generates an immune response against the causative HPV strains. It uses ...

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

A new study, led by researchers at Children's Hospital of Philadelphia (CHOP), identified tiny pieces of messenger RNA that ...

Teddi Mellencamp's health update revealed she's experiencing a symptom she believes could be from immunotherapy. Read.

Zopapogene imadenovec is a non-replicating adenoviral vector-based immunotherapy designed to induce an immune response against HPV 6 and HPV 11 proteins.

The FDA has granted full approval to Precigen’s Papzimeos (zopapogene imadenovec-drba) for adults with recurrent respiratory papillomatosis (RRP). Papzimeos is a non-replicating adenoviral ...

A Medical University of South Carolina team reports in Frontiers in Immunology that it has engineered a new type of ...

Teddi's followers have her back. The post Teddi Mellencamp Experiencing ‘Severe Anxiety’ Amid Immunotherapy Treatment ...

The FDA approved the adenoviral vector-based immunotherapy, zopapogene imadenovec-drba, for treatment of certain patients ...